| pubmed-article:15791143 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15791143 | lifeskim:mentions | umls-concept:C0003826 | lld:lifeskim |
| pubmed-article:15791143 | lifeskim:mentions | umls-concept:C0232910 | lld:lifeskim |
| pubmed-article:15791143 | lifeskim:mentions | umls-concept:C1442792 | lld:lifeskim |
| pubmed-article:15791143 | lifeskim:mentions | umls-concept:C0003299 | lld:lifeskim |
| pubmed-article:15791143 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:15791143 | pubmed:dateCreated | 2005-3-25 | lld:pubmed |
| pubmed-article:15791143 | pubmed:abstractText | Information on the risks associated with antiepileptic drug (AED) use in pregnancy is necessary for a rational approach to the management of women of childbearing potential who have epilepsy. This reviews addresses recent reports on the risk for birth defects and impaired postnatal development attributable to prenatal exposure to AEDs. | lld:pubmed |
| pubmed-article:15791143 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15791143 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15791143 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15791143 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15791143 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15791143 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15791143 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:15791143 | pubmed:issn | 1350-7540 | lld:pubmed |
| pubmed-article:15791143 | pubmed:author | pubmed-author:TomsonTorbjör... | lld:pubmed |
| pubmed-article:15791143 | pubmed:author | pubmed-author:BattinoDinaD | lld:pubmed |
| pubmed-article:15791143 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15791143 | pubmed:volume | 18 | lld:pubmed |
| pubmed-article:15791143 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15791143 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15791143 | pubmed:pagination | 135-40 | lld:pubmed |
| pubmed-article:15791143 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:15791143 | pubmed:meshHeading | pubmed-meshheading:15791143... | lld:pubmed |
| pubmed-article:15791143 | pubmed:meshHeading | pubmed-meshheading:15791143... | lld:pubmed |
| pubmed-article:15791143 | pubmed:meshHeading | pubmed-meshheading:15791143... | lld:pubmed |
| pubmed-article:15791143 | pubmed:meshHeading | pubmed-meshheading:15791143... | lld:pubmed |
| pubmed-article:15791143 | pubmed:meshHeading | pubmed-meshheading:15791143... | lld:pubmed |
| pubmed-article:15791143 | pubmed:meshHeading | pubmed-meshheading:15791143... | lld:pubmed |
| pubmed-article:15791143 | pubmed:meshHeading | pubmed-meshheading:15791143... | lld:pubmed |
| pubmed-article:15791143 | pubmed:meshHeading | pubmed-meshheading:15791143... | lld:pubmed |
| pubmed-article:15791143 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:15791143 | pubmed:articleTitle | Teratogenicity of antiepileptic drugs: state of the art. | lld:pubmed |
| pubmed-article:15791143 | pubmed:affiliation | Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden. torbjorn.tomson@karolinska.se | lld:pubmed |
| pubmed-article:15791143 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15791143 | pubmed:publicationType | Review | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15791143 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15791143 | lld:pubmed |
